A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF A HUMAN MONOCLONAL ANTIBODY, REGN2222, FOR THE PREVENTION OF MEDICALLY ATTENDED RSV INFECTION IN PRETERM INFANTS
Principal Investigator(s)
Odom,Michael W
Funded by
REGENERON PHARMACEUTICALS
Research Start Date
Status
Inactive